XML 12 R5.htm IDEA: XBRL DOCUMENT v3.25.1
Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Operating Activities:    
Net loss $ (12,827) $ (6,494)
Adjustments to reconcile net loss to net cash used in operating activities:    
Depreciation and amortization [note 3] 62 57
Stock-based compensation [note 7[c], note 7[e] and note 7[f]] 2,232 1,288
Accrued interest on 2023 SVB convertible term loan [note 6]   318
Amortization of 2024 SVB convertible term loan transaction costs [note 6] 14  
Accretion of discount on modification of debt   161
Change in fair value of contingent consideration [note 4 and note 5] 91 52
Changes in operating assets and liabilities:    
Prepaid expenses and other assets 85 92
Accounts payable (293) (245)
Accrued liabilities other 732 686
Accrued clinical liabilities 879 245
Accrued compensation (2,064) (1,447)
Lease obligation [note 8] 1 (1)
Net cash used in operating activities (11,088) (5,288)
Financing Activities:    
Net cash provided by financing activities   56,110
Investing Activities:    
Purchase of marketable securities (3,363)  
Maturities of marketable securities 14,716  
Net cash used in investing activities 11,353  
Effect of exchange rate changes on cash (2)  
Net increase/(decrease) in cash, cash equivalents and restricted cash 263 50,822
Cash, cash equivalents and restricted cash at beginning of the period 12,773 15,596
Cash, cash equivalents and restricted cash at end of the period $ 13,036 66,418
February 2024 Registered Direct Offering [Member]    
Financing Activities:    
Proceeds from registered direct offering, net of issuance costs   $ 56,110